Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Judge OKs OxyContin maker Purdue Pharma's criminal sentence, a last step before it dissolves
NEWARK, N.J. — OxyContin maker Purdue Pharma is set to be dissolved and replaced by a company focused on the public good by the week's end, as a massive legal settlement resolving thousands of lawsuits takes effect. A federal judge on…
OxyContin maker Purdue Pharma's criminal sentence could be the last step before company dissolves
OxyContin maker Purdue Pharma could be dissolved and replaced by a company focused on the public good by the end of the week, as a massive legal settlement resolving thousands of lawsuits is set to take effect. A federal judge on Tuesday is…
Piramal Pharma Limited Announces Results for Q4 and Full-year FY26
MUMBAI, India, April 28, 2026 /CNW/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and…
OxyContin maker Purdue Pharma's criminal sentence could be the last step before company dissolves
Email Address: I agree to the Terms and Conditions, Cookie and Privacy Policies, and CASL agreement. Already have an account? Log in here - To continue reading, please subscribe: Enjoy unlimited reading on winnipegfreepress.com Read the E-Edition…
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
Company announcement – No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people living with…
Judge approves OxyContin maker Purdue Pharma's criminal sentence, a last step before it dissolves
OxyContin maker Purdue Pharma is set to be dissolved and replaced by a company focused on the public good by the week's end, as a massive legal settlement resolving thousands of lawsuits takes effect. A federal judge on Tuesday delivered a criminal…
Nuvectis Pharma (NVCT) Projected to Post Earnings on Tuesday
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Nuvectis Pharma to post earnings of ($0.30) per share for the quarter. Individuals may review…
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 8% - What's Next?
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report)'s stock price traded down 8% during mid-day trading on Tuesday. The stock traded as low as $28.03 and last traded at $28.0210. 743,035 shares were traded during trading, a decline of…
BridgeBio Pharma (NASDAQ:BBIO) Earns 'Outperform' Rating from Mizuho
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report)'s stock had its 'outperform' rating reaffirmed by Mizuho in a note issued to investors on Tuesday, Benzinga reports. They currently have a $106.00 price objective on the stock. Mizuho's target price…
Pharmalittle: We're reading about warnings over Trump's MFN plan, Purdue Pharma sentencing, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where clear blue skies and pleasant breezes are greeting us. Who could ask for anything more? Actually, we could —…
Ascendis Pharma A/S (NASDAQ:ASND) Sees Unusually-High Trading Volume - Here's What Happened
Shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) saw unusually-strong trading volume on Tuesday. Approximately 1,372,202 shares changed hands during mid-day trading, an increase of 99% from the previous session's volume of 688,497…
Doximity: Buy It As Mr. Market Is Selling It Cheap Under A Panic Attack (NYSE:DOCS)
Doximity has seen a two-thirds stock price decline, which I attribute mainly to market overreaction and short-term uncertainty, not deteriorating fundamentals. DOCS maintains a robust business model with 90% gross margins, ~30% net margins, strong…
Novartis Could Upgrade Future Growth Outlook
backed its 2026 guidance and raised the prospect of upgrading its mid- to long-term growth outlook as it receives data in the second half of the year from multiple drug trials. The Swiss pharmaceutical company said Tuesday that competition from…
Indian Stock Market Decline: Oil Price, FII Outflows, Banking Sector Woes
Indian stock markets, including the Sensex and Nifty, experienced a notable decline driven by surging crude oil prices, significant foreign institutional investor (FII) outflows, and regulatory pressures on the banking sector. Indian benchmark…
Pharmaceutical company suddenly buries new factory in Muttenz
A major industrial project in Baselland is off the table: Corden Pharma is stopping the construction of a new chemical plant in Muttenz. Behind the scenes, there are many indications that US trade policy under Donald Trump played a decisive role.
Receive a Daily briefing on Pharma Industry News
Get Started